Back to GetFilings.com



Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 


 

FORM 10-Q

 


 

(Mark One)

x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the quarterly period ended June 30, 2004

 

¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

For the transition period from            to            

 

Commission file number: 000-30267

 


 

ORCHID BIOSCIENCES, INC.

(Exact name of registrant as specified in its charter)

 


 

Delaware   22-3392819

(State or other jurisdiction of

incorporation or organization)

 

(I.R.S. Employer

Identification No.)

4390 US Route One

Princeton, NJ

  08540
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (609) 750-2200

 


 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  ¨

 

Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule 12b-2 of the Exchange Act).    ¨  Yes    x  No

 

As of August 4, 2004, the registrant had 22,376,421 shares of common stock outstanding.

 



Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

 

INDEX TO FORM 10-Q

 

          Page

     PART I. FINANCIAL INFORMATION     

ITEM 1.

  

Financial Statements

   3
    

Consolidated Balance Sheets as of June 30, 2004 and December 31, 2003 (unaudited)

   3
     Consolidated Statement of Operations for the three and six months ended June 30, 2004 and 2003 (unaudited)    4
     Consolidated Statement of Cash Flows for six months ended June 30, 2004 and 2003 (unaudited)    5
     Consolidated Statement of Stockholders’ Equity and Comprehensive Income (Loss) for the six months ended June 30, 2004 (unaudited)    6
     Notes to Consolidated Financial Statements (unaudited)    7

ITEM 2.

   Management’s Discussion and Analysis of Financial Condition and Results of Operations    20

ITEM 3.

   Quantitative and Qualitative Disclosures about Market Risk    31

ITEM 4.

   Controls and Procedures    31
     PART II OTHER INFORMATION     

ITEM 1.

  

Legal Proceedings

   33

ITEM 2.

  

Changes in Securities, Use of Proceeds and Issuers Purchases of Equity Securities

   33

ITEM 3.

  

Defaults Upon Senior Securities

   34

ITEM 4.

  

Submission to Matters of Vote to Security Holders

   34

ITEM 5.

  

Other Information

   34

ITEM 6.

  

Exhibits and Reports on Form 8-K

   34

 

2


Table of Contents

PART I – FINANCIAL INFORMATION

 

Item 1. FINANCIAL STATEMENTS

 

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

 

Consolidated Balance Sheets

(unaudited)

(In thousands, except share and per share data)

 

    

June 30,

2004


   

December 31,

2003


 
Assets                 

Current assets:

                

Cash and cash equivalents

   $ 31,117     $ 9,938  

Restricted cash

     218       953  

Accounts receivable, net

     10,768       9,976  

Inventory

     1,737       1,172  

Prepaids and other current assets

     1,580       2,583  

Assets of a business component held for sale

     —         4,595  
    


 


Total current assets

     45,420       29,217  

Fixed assets, net

     10,511       11,071  

Goodwill, net

     2,706       2,686  

Other intangibles, net

     14,067       14,942  

Restricted cash

     1,769       1,113  

Other assets

     157       400  
    


 


Total assets

   $ 74,630     $ 59,429  
    


 


Liabilities and Stockholders’ Equity                 

Current liabilities:

                

Accounts payable

   $ 4,076     $ 4,768  

Accrued expenses

     11,794       9,971  

Current portion of long-term debt

     921       1,889  

Deferred revenue

     1,506       1,812  

Liabilities of a business component held for sale

     —         3,156  
    


 


Total current liabilities

     18,297       21,596  

Long-term debt, less current portion

     137       415  

Accrued restructuring, less current portion

     1,440       782  

Other liabilities

     2,050       1,592  
    


 


Total liabilities

     21,924       24,385  

Redeemable Convertible Series A preferred stock;

                

Designated 1,680 shares: $.001 per share par value; 0 and 1,675 shares issued as of June 30, 2004 and December 31, 2003, respectively; 0 and 503 shares outstanding as of June 30, 2004 and December 31, 2003, respectively; stated, minimum redemption and liquidation value of $5,025

     —         3,897  

Commitments and contingencies

                

Stockholders’ equity:

                

Preferred stock, $.001 par value. Authorized 5,000,000 shares designated 1,680 shares of redeemable convertible Series A preferred stock, and 1,675 shares issued as of June 30, 2004 and December 31, 2003, respectively and 503 shares outstanding as of December 31, 2003

     —         —    

Series A junior participating preferred stock, $.001 par value. Designated 1,000,000 shares; no shares issued or outstanding

                

Common stock, $0.001 par value. Authorized 150,000,000 shares; issued and outstanding 22,295,237 and 16,717,498 at June 30, 2004 and December 31, 2003, respectively

     22       16  

Common stock, $0.001 par value. 20,115 shares to be issued as of December 31, 2003

     —         149  

Additional paid-in capital

     347,440       317,055  

Deferred compensation

     —         (212 )

Accumulated other comprehensive income

     1,831       1,641  

Accumulated deficit

     (296,587 )     (287,502 )
    


 


Total stockholders’ equity

     52,706       31,147  
    


 


Total liabilities and stockholders’ equity

   $ 74,630     $ 59,429  
    


 


 

See accompanying notes to consolidated financial statements.

 

3


Table of Contents

ORCHID BIOSCIENCES, INC. AND SUBSIDIARIES

Consolidated Statements of Operations

Three and six months ended June 30, 2004 and 2003

(In thousands, except per share data)

(unaudited)

 

     Three months ended June 30,

     Six months ended June 30,

 
     2004

    2003

     2004

    2003

 

Revenues:

                                 

Service revenues

   $ 14,833     $ 12,244      $ 28,127     $ 24,785  

Other revenues

     124       120        298       317  
    


 


  


 


Total revenues

     14,957       12,364        28,425       25,102  
    


 


  


 


Operating expenses:

                                 

Cost of service revenues

     8,206       6,653        16,549       13,650  

Research and development

     454       1,159        871       2,364  

Marketing and sales

     2,019       1,701        3,745       3,569  

General and administrative

     5,229       6,456        12,763       12,416  

Impairment of assets

     —         837        —         837  

Restructuring

     —         (83 )      1,130       (83 )

Amortization of intangible assets

     452       453        904       908  
    


 


  


 


Total operating expenses

     16,360       17,176        35,962       33,661  
    


 


  


 


Operating loss

     (1,403 )     (4,812 )      (7,537 )     (8,559 )

Other income (expense):

                                 

Interest income

     46       49        55       62  

Interest expense

     (42 )     (147 )      (97 )     (300 )

Other income/(expense)

     17       141        (100 )     291  
    


 


  


 


Total other income/(expense), net

     21       43        (142 )     53  
    


 


  


 


Loss from continuing operations before income taxes

     (1,382 )     (4,769 )      (7,679 )     (8,506 )

Income tax expense

     (421 )     (716 )      (556 )     (1,060 )
    


 


  


 


Loss from continuing operations

     (1,803 )     (5,485 )      (8,235 )     (9,566 )

Discontinued operations:

                                 

Loss from operations of a business held for sale

     (343 )     (3,983 )      (850 )     (4,182 )
    


 


  


 


Net loss

     (2,146 )     (9,468 )      (9,085 )     (13,748 )

Dividends to Series A preferred shareholders

     —         (244 )      (14 )     (244 )

Accretion of Series A preferred stock discount

     —         (471 )      (1,129 )     (471 )

Beneficial conversion feature of redeemable Series A preferred stock

     —         —          —         (744 )
    


 


  


 


Net loss allocable to common stockholders

   $ (2,146 )   $ (10,183 )    $ (10,228 )   $ (15,207 )
    


 


  


 


Basic and diluted loss from continuing operations per share allocable to common stockholders

   $ (0.08 )   $ (0.55 )    $ (0.45 )   $ (0.98 )

Basic and diluted loss from discontinued operations per share

   $ (0.02 )   $ (0.35 )    $ (0.04 )   $ (0.37 )

Basic and diluted net loss per share allocable to common stockholders

   $ (0.10 )   $ (0.90 )    $ (0.49 )   $ (1.35 )

Shares used in computing basic and diluted net loss per share allocable to common stockholders

     22,252       11,374        20,952       11,261  

 

See accompanying notes to consolidated financial statements.

 

4


Table of Contents

Consolidated Statements of Cash Flows

Six months ended June 30, 2004 and 2003

(In thousands)

(unaudited)

 

     2004

    2003

 

Cash flows from operating activities:

                

Loss from continuing operations

   $ (8,235 )   $ (9,566 )

Loss from discontinued operations

     (850 )     (4,182 )

Adjustments to reconcile net loss to net cash used in operating activities:

                

Cash provided by discontinued operations

     —         (586 )

Noncash compensation expense

     212       981  

Depreciation and amortization

     2,723       3,130  

Non cash expense for warrants issued as a financing fee and modification of stock options

     —         133  

Impairment of discontinued assets

     —         3,905  

Impairment of assets

     —         837  

Bad debt expense

     48       —    

Loss of sale of investment

     125